Oral Oxytocin's Effects on Attention Control
Oral Oxytocin's Effects on Attention Control: An Eye-tracking Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Zhuang Qian, MD
- Phone Number: 13086663679
- Email: zq19910362@126.com
Study Contact Backup
- Name: Xu Xiaolei, PhD
- Phone Number: 18780140034
- Email: rabby_uestc@outlook.com
Study Locations
-
-
Sichuan
-
Chengdu, Sichuan, China, 611731
- Recruiting
- University of Electronic Science and Technology of China(UESTC)
-
Contact:
- Zhao Weihua, PhD
- Phone Number: +86 2861 830 811
- Email: zarazhao.uestc@outlook.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male, healthy participants
- Non smokers
Exclusion Criteria:
- Previous or current medical, psychiatric, neurological disorder
- Regular medication
- Use of any psychoactive substances in the 24 hours before experiment
- Contra-indications for oxytocin
- Contra-indications for eye-tracking data acquisition
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Oral Oxytocin
Oxytocin orally (24 IU)
|
Administration of oxytocin orally (24 IU)
|
|
Placebo Comparator: Oral Placebo
Placebo orally (24 IU, identical ingredients, except the active agent)
|
Administration of placebo orally (24 IU)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Effect of oral oxytocin administration on saccade/antisaccade latencies towards social (facial) versus non-social (shape) stimuli
Time Frame: 45 minutes - 100 minutes after treatment
|
Comparison between social-specific saccade/antisaccade latencies (in milliseconds) between the oxytocin and placebo treatment conditions
|
45 minutes - 100 minutes after treatment
|
|
Effect of oral oxytocin administration on error rates of saccade/antisaccade for social (facial) versus non-social (shape) stimuli
Time Frame: 45 minutes - 100 minutes after treatment
|
Comparison between social-specific error rates of saccade/antisaccade between the oxytocin and placebo treatment conditions.
|
45 minutes - 100 minutes after treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Emotion-specific effects of oral oxytocin administration on saccade/antisaccade latencies towards the separate facial emotions
Time Frame: 45 minutes - 100 minutes after treatment
|
Comparison between emotion-specific saccade/antisaccade latencies (in milliseconds) between the oxytocin and placebo treatment conditions
|
45 minutes - 100 minutes after treatment
|
|
Emotion-specific effects of oral oxytocin administration on saccade/antisaccade error rates for the separate facial emotions
Time Frame: 45 minutes - 100 minutes after treatment
|
Comparison between emotion-specific saccade/antisaccade error rates between the oxytocin and placebo treatment conditions
|
45 minutes - 100 minutes after treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Keith Kendrick, PhD, University of Electronic Science and Technology of China (UESTC)
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- UESTC-neuSCAN-69
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.